Luis Raez: We have a lot of survivors on osimertinib alone that will need second-line therapy in the future
Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post on X by Stephen Liu, Associate Professor of Medicine at Georgetown University, about a recent paper by Benjamin Besse et al. published in Journal of Thoracic Oncology:
Authors: Benjamin Besse, Koichi Goto, Yongsheng Wang, Roland Knoblauch, Byoung Chul Cho et al.
“This study is very important because even this regimen is approved for the first line, we have a lot of survivors on osimertinib alone that will need second-line therapy in the future.”
Quoting Stephen Liu’s post:
“CHRYSALIS-2 Cohort A: amivantamab plus lazertinib in EGFR NSCLC after osimertinib and chemotherapy (n=162). BICR RR 35%, CBR 58%, DOR 8.3m, PFS 4.5m, OS 14.8m, and CNS efficacy noted. AEs included rash in 81% (G3 10%), paronychia in 52%.”
More posts featuring Luis Raez and Stephen Liu.
Dr. Luis E. Raez is the Medical Director and Chief Scientific Officer at Memorial Cancer Institute, part of Memorial Healthcare System. He specializes in treating lung and head and neck cancers and leads the Thoracic Oncology Program as Director.
Dr. Raez is also a clinical professor of medicine at Florida International University (FIU), a research professor at Florida Atlantic University (FAU), and a visiting professor of medicine at Cayetano Heredia University (UPCH) in Peru.
Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.
Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
Benjamin Besse is the Head of Clinical Research at Gustave Roussy and a Full Professor of Medical Oncology at University of Paris-Saclay. He serves as the Chair of the Scientific Council at EORTC and is the Coordinator of RYTHMIC, the French thymic malignancies network.
His research is centered on personalized therapeutic strategies, focusing on molecular abnormalities, circulating biomarkers, and early drug development for thymic malignancies and thoracic tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023